Introduction
Breakthrough advances in the treatment of medical illness require the elucidation of the pathogenic mechanisms initiating and driving disease states. Cancer is largely a disease of the genome, and through recent technological advances, we are now able to separate the ''diseased'' cancer genome from the normal genome. As a consequence, the next decade should see dissection of disease-relevant somatic mutations and the completion of the ''pathogenetic'' landscape of cancer, paving the way for further therapeutic development.
The discovery of key pathogenetic cancer alterations has already transformed the treatment of specific cancer types. The introduction of all-trans retinoic acid to the treatment of acute promyelocytic leukemia harboring translocations into the RARa gene has led to curative responses in the majority of patients (Huang et al., 1988) . Treatment of chronic myelogenous leukemia, bearing the BCR-ABL fusion gene, with imatinib, an inhibitor of the Abelson kinase, has led to a staggering 80% decline in disease mortality ( Figure 1 ). More recently, inhibitors targeting EGFR mutations in adenocarcinoma of the lung, BRAF mutations in melanoma, and ALK translocations in lung cancer highlight the potential to alter the course of previously untreatable disease (reviewed in Haber et al., 2011) . These encouraging results strongly suggest that the next step toward the goal of curing cancer is to more fully exploit this genetic-therapeutic strategy.
Though access to ever-increasing amounts of sequence information holds great promise, there are at least five significant barriers to this goal. First, we do not yet have a complete picture of the genetic alterations comprising the disordered cancer genome. Second, the discovery of specific mutations that lead to cancer, so called ''driver'' mutations, is too often accompanied by an inability to create a relevant therapeutic molecule. In other words, there is a ''druggability gap.'' Third, most cancers, particularly those that are late stage, are genetically heterogeneous or capable of rapid genetic evolution. Either scenario can lead to the rapid emergence of therapeutic resistance. Fourth, as a corollary to the problem of resistance, combination therapy will be required to achieve therapeutic cure or long-lasting disease control. Finally, the ability to make more definitive predictions about clinical therapeutic outcome is severely limited by the lack of robust preclinical disease models.
''Completing'' the Human Cancer Genome The daunting complexity of the human cancer genome is amply illustrated by the emerging fully characterized cancer genomes. For example, a recent study looking at prostate cancer identified substantial variation between the patient tumors ( Figure 2) (Berger et al., 2011) . This complexity appears both as the diversity of genetic alterations across many cancer types and samples and the complexity within single tumors, in which the background mutation frequency (''carrier'' mutations) often exceeds the frequency of ''driver'' mutations. Thus, in order to distinguish the critical genetic alterations of therapeutic interest, repetitive mutations or repetitively mutated genes across many samples from individual tumor types must be identified and correlated with disease in a relevant manner.
One can envision a broader goal requiring larger sample sets whereby we would define not only the cancer gene alterations, but also the cancer gene interactions. As examples, early efforts to describe the glioblastoma genome identified three core interacting genetic pathways in this disease (The Cancer Genome Atlas Research Network, 2008) , whereas low-frequency single-gene mutations appear to, in aggregate, target the NFKB pathway in myeloma (Chapman et al., 2011) . Therefore, the vision of ''completeness'' is to characterize cancer genomes at a sufficient scale so that genetic interactions can be used to directly define the key functional cancer pathways and potentially the therapeutic targets.
To this end, the goal should be to describe three interaction attributes beyond single-gene mutation frequency, specifically: (1) to identify those genetic alterations that co-occur at a greater frequency than by chance alone and are hence cooperative, (2) to identify those genes in which alterations anticorrelate and thus provide a similar function or where co-mutation is incompatible with cancer cell progression, and (3) to identify genes whose coding sequence is notable for the absence of background mutations. In this latter case, the absence of background loss-of-function mutations could potentially define genes whose function is absolutely required for cancer cell survival. This so-called class of ''never-mutated'' genes will likely be conditioned by driver genetic events and could be an important new class of ''conditional lethality'' genes particularly relevant to therapeutic development. Advances in sequencing technology have created the opportunity to achieve these goals; however, high-priority efforts must now be made to address the remaining ratelimiting steps of tumor sample acquisition, data handling, and data analysis.
From Genetics to Therapy: Bridging the Druggability Gap The identification of protein kinases, activated by somatic mutation, has led the recent wave of therapeutic breakthroughs outlined above. In sharp contrast is the realization that most of the known critical oncogenes and tumor suppressors remain beyond the reach of current therapeutic modalities. Sequencing projects have reaffirmed TP53 as the most commonly mutated tumor suppressor gene and the RAS oncogenes (K-RAS and N-RAS) as key drivers of a variety of devastating cancers. Yet, the elucidation of p53 and RAS biology has not been coupled with major revolutions in therapeutics based on these genetic alterations. Similarly, the discovery of key oncogenic transcription factors, including MYC, NMYC, ERG, and others, has not been paralleled by the development of transcription factor inhibitors. To address this druggabilty gap, it is first necessary that we challenge the notion of what is ''undruggable'' so that drug targets are not rejected outright based on prior assumptions (or past failures). Similar prejudices led to the premature conclusions that kinases and other ATPutilizing enzymes were themselves undruggable. The development of drugs disrupting protein-protein interactions (PPI) between IAPs and SMAC (Sun et al., 2004) , between p53 and HDM2 (Vassilev et al., 2004) , and, most notably, along the remarkably extended interface between BH3-containing proteins and BCL2 family members belie the notion that such PPI targets are inherently intractable (Oltersdorf et al., 2005) .
Further broadening of the scope of druggable targets can be achieved through a number of parallel mechanisms. In the arena of ''typical'' synthetic lowmolecular weight molecules, we will benefit from increases in diversity and scale of available small-molecule libraries. In academia, renewed interest in direct participation in drug discovery has enabled establishment of modestscale low-molecular weight screening facilities. Such efforts may focus on phenotype-oriented drug discovery, and hopefully breakthroughs against difficult targets will follow. But centers must be bolstered with robust medicinal chemistry resources, or it will become difficult to make advances beyond the relatively weak nonspecific inhibitors typically identified through screening. The most challenging drug discovery projects (e.g., PPIs) typically require structure-based guidance (X-ray and NMR) and an investment in biophysical analysis platforms. Indeed, in tackling challenging drug targets, it is likely that these resources will be of more value than the screening platforms themselves.
In industry, time-dependent pressure to deliver molecules ready for clinical trials drives early-stage drug discovery efforts focused on tractable targets, including those with often tenuous links to disease pathogenesis over those focused on difficult targets with incontrovertible disease linkage. Perversely, this can reward a scenario of costly late-clinical failure based on the invalidation of the therapeutic hypothesis over a scenario of early-research failure based on druggability. Notably, the current biotechnology venture-based funding model suffers from the same short-term reward structure. Somehow, a proportion of the biopharmaceutical drug discovery resource must be dedicated over the longer term to the discovery of compounds that break new ground against the most challenging of targets. To expand these efforts on the small molecule front for particular targets, we need research funding mechanisms in academia or industry that are compatible with the 5-10 year timescale required for tackling difficult drug discovery problems.
Alternative therapeutic modalities, including therapeutic siRNA, intracellular peptide therapies, and gene therapy, hold promise for a broad attack on the druggability gap but are all beset by a common issue: difficult drug delivery. The challenge to the delivery of therapeutic siRNA remains essentially unchanged from that faced by antisense oligonucleotides. The molecules are large (>10,000 MW) and highly charged, making distribution across biological membranes problematic (Shim and Kwon, 2010) . To realize the promises for these novel therapeutic classes, a renewed focus on systematic and robust approaches to the delivery problem is warranted.
In the short-term, certain key cancer genes are likely to remain relatively difficult to drug. This is a notable problem for the Shown are the estimated US-based CML incidence and mortality rates for the years 1997, 1998, and 2000-2011 . These data were abstracted from the annual cancer statistics publications published by CA: A Cancer Journal for Clinicians' in the years 1997 , 1998 , and 2000 (Siegel et al., 2011 tumor suppressor genes, in which the gene product is often completely absent. Here, the hope is to exploit the concept of ''synthetic lethality'' or ''conditional lethality'' in order to define key therapeutic targets whose requirement for the maintenance of the cancer state is conditioned by a specific genetic event (Kaelin, 2005) . Such conditional lethality nodes can be conceived of as existing within a pathway downstream of an oncogene or tumor suppressor or in a parallel pathway. In the case of downstream conditional lethality, preclinical and clinical proof of concept has been obtained from the inhibition of the SMO receptor downstream of tumor suppressor mutations in the PTCH gene (Von Hoff et al., 2009) , from the inhibition of mTORC1 downstream of germline mutations in the TSC genes (Krueger et al., 2010) , and from the inhibition of MEK downstream of mutant oncogenic BRAF in melanoma (Solit et al., 2006) . In the case of parallel pathway conditional lethality, clinical proof of concept has been obtained from the inhibition of PARP1 in the context of BRCA1 loss-offunction mutations in breast cancer (Farmer et al., 2005; Fong et al., 2009 ). In each case, the key finding is that mutantbearing tumors are far more susceptible to the relevant inhibitor than either nonmutant tumors or the normal host tissue.
The tools for further discovery of such conditional lethal nodes are only just becoming available with improvements in larger-scale shRNA libraries. However, the robust realization of such discoveries remains plagued by the noise inherent in larger-scale shRNA screens and, in some cases, the overreliance on screens in isogenic cell line pairs that can often lead to cell line-specific hits. In this regard, the alternative approach of cell line panels should be considered (Brough et al., 2011 ). An investment in the development of highly validated shRNAs for each human and murine gene could go a long way in helping to reduce the notion of conditional lethality to practical discovery.
The Development of Resistance
The evolutionary nature of cancer and its mutable genome makes emergent therapeutic resistance a serious and often unnerving problem. No doubt this is a major hurdle in moving from therapeutic efficacy to curative cancer therapy. Though there has been a notable lack of progress in defining clinically relevant mechanisms of resistance to classical cytotoxics, more rapid progress has been seen in understanding resistance to genetically directed targeted therapeutics. In particular, it is clear that, in the latter case, the preclinical discovery of resistance mechanisms can be directly predictive of the resistance features seen in patients. A first example was the elucidation of mechanisms of resistance to imatinib, in which the preclinical definition of resistance alleles through a random mutagenesis and selection process was, in retrospect, highly correlated with resistance alleles uncovered in patient samples (Azam et al., 2003; Shah et al., 2002) . Similarly, clinically relevant mechanisms of resistance to EGFR, SMO, and RAF inhibitors have been uncovered through a variety of preclinical studies employing the relevant addicted cell line or animal models. In parallel, the application of next-generation sequencing technologies to the discovery of very low-abundance pre-existing resistance alleles can allow confirmation of preclinical discoveries prior to treatment with relevant inhibitors.
The utility of predictive preclinical resistance studies together with the advent of deep sequencing raise the possibility that resistance mechanisms could be identified before the clinical trials of novel therapeutics begin. In fact, ideally such an approach would be used to guide improvements in the first-generation inhibitors during lead optimization. For example, choices among distinct small-molecule scaffold classes with alternate binding modes to a target of interest could be prioritized based on the frequency and propensity of resistance mechanisms and upon which resistance alleles are detectable in patients prior to treatment. Presumably, this approach could accelerate the generation of bestin-class targeted therapeutics.
The rapid emergence of resistance during targeted therapy has raised the specter of an endless chase of resistance alleles, with ever more specific inhibitors dealing with an increasing complex spectrum of resistance alleles and nongenetic tumor-adaptive responses. Though this so-called ''whack-a-mole'' approach can lead to the rapid clinical development of second-generation or third-generation inhibitors applied in mutation-specific settings, this will not be the ultimate strategy for achieving curative therapy. Rather, defining the emergent principles of resistance should be used to both (1) guide improvements to the first-line targeted therapeutics to gain-greater efficacy and (2) elucidate rationale combinations based on the understanding of escape mechanisms.
What can we say about the principles of resistance to targeted therapeutics that are now evident from the study of ABL, EGFR, KIT, BRAF, and SMO inhibitors? The common theme is a fairly remarkable and consistent finding of persistent target and pathway addiction. Given the complexity of the cancer genome and the well-recognized mutability, one might have imagined that hundreds of distinct resistance mechanisms would have emerged in response to any given targeted therapy. Instead, the observation is that of a consistent pattern of resistance mechanisms, acting in large part to restore the activity of the original ''addicting'' pathway. In the case of imatinibbased treatment of CML, the great majority of resistance alleles are found in the ABL kinase domain itself. Based on these data, ABL inhibitors capable of both directly suppressing such mutations and more potently inhibiting the wild-type kinase have substantially improved the molecular response rates (Kantarjian et al., 2010; Saglio et al., 2010) . Lung adenocarcinomas bearing activating mutations in EGFR show dramatic response to catalytic EGFR inhibitors but relapse through direct mutations in the EGFR kinase domain or through coamplification of MET (Kobayashi et al., 2005; Pao et al., 2005) . In both instances, a common feature is the restoration of downstream signaling through phosphoinositide-3 kinase. Based on these data, second-generation inhibitors, novel combinations with MET inhibitors and with PI3K inhibitors, are in development. Melanomas bearing activating mutations in BRAF similarly manifest significant responses to BRAF or MEK inhibitors, and through heterogeneous mechanisms, escape is manifest largely by reactivation of the MEK-ERK cascade. Finally, the study of resistance to the androgen receptor pathway inhibitors in prostate cancer for two decades has focused on so-called androgen-independent means of resistance. The recent clinical success of CYP17 inhibitors (Attard et al., 2008) and novel AR antagonists (Scher et al., 2010) has shown, however, that such ''androgen-independent'' tumors remain dependent on both AR and AR ligands. In all, the emerging data from these examples and others strongly support the notion that cancers remain highly dependent on these initial dominant oncogenic pathways and support the elaboration of improved inhibitors or of ''vertical'' pathway combinations, where inhibitors target the same pathway, as at least one mechanism by which we can improve the first-line treatment of cancer. Such combinations are also likely to be effective in the case of nongenetic or adaptive resistance mechanisms involving pharmacologic activation of homeostatic feedback loops exemplified by the finding of RTK activation induced by AKT inhibition (Chandarlapaty et al., 2011) .
Toward the Discovery and Development of Curative Combinations
The majority of curative cancer treatment regimens involve multidrug combinations. The emergence of therapeutic resistance together with the frequent incomplete response to primary therapy underscores the importance of developing novel highly efficacious combinations. Here, we face substantial challenges in both the research arena and the clinic.
The preclinical discovery of combination therapies is significantly limited by experimental throughput and by the lack of a consistent understanding of which measures of preclinical combination activity might be predictive of clinical combination activity. The throughput of combination profiling in vitro might be solved through automation; however, animal costs rapidly become prohibitive if systematic in vivo combination testing is required. Measures of combination effect, i.e., the interaction between two drugs to produce a cellular outcome, have become increasingly sophisticated, yet there is little understanding of how such improved methods will relate to the clinic. Efforts to solve this latter problem are urgently needed.
The clinical challenge is to move beyond the paradigm that requires the testing of new agents in combination with existing standard of care therapies (SOCs). This incremental strategy ignores the possibilities that novel and existing agents might be antagonistic and that two novel agents might be more effective as a combination without an SOC component. Fortunately, recognition that this paradigm is inadequate has led to early phase II clinical trials in which two novel agents are being tested in combination prior to the full demonstration of single-agent activity. Notably, the observation that the treatment of RASdriven tumors may require blockade of both the PI3K and RAS pathways (Engelman et al., 2008) has led to multiple trials of the ''horizontal'' combination of AKT or PI3K inhibitors in combination with MEK inhibitors. In addition, the ''vertical'' combination of MEK and RAF inhibitors is being tried in melanoma (Infante et al., 2011) . If future results of such phase II trials were truly distinctive, including high partial and perhaps complete response rates in relatively unresponsive cancers, such combinations might be directly submitted as new drug applications or might proceed to phase III trials comparing new combinations against the accepted standard of care.
The Development of Preclinical Disease Model Systems
Until recently, preclinical therapeutic profiling was typically confined to the analysis of a handful of human cancer cell lines. As such, preclinical testing is conducted on fewer cancer cell lines than the number of human patients treated in even exploratory trials. Under such conditions, it is unreasonable to expect either robust preclinical prediction of the clinical utility of a candidate therapeutic or the preclinical discovery and validation of predictive biomarkers. In simple terms, the test sets are too small.
Ideally, preclinical models would be of sufficient robustness and used at sufficient scale so that clinical failure would be reduced to zero. The complexity of human cancer makes it unlikely that this landmark will be attained; nonetheless, progress toward this goal will be of unquestionable benefit. The ''required'' elements of a robust preclinical infrastructure include molecularly defined model systems that are directly reflective of their human counterparts and sufficient model numbers for one to approach the disease diversity found in humans. Additionally, the preservation of stromal-epithelial interactions, in particular those occurring through ligand-receptor pairs, along with the ability to study cancer in the setting of a functioning immune system, are vitally important. Lastly, the ability to replicate disease progression and to examine sufficient intratumoral heterogeneity to enable the study of resistance are desirable for such an infrastructure. It is selfevident that no single class of preclinical models will satisfy such requirements. Moreover, each model system will have distinct advantages and weaknesses. Thus, the monolithic view that there is a single best system for the preclinical study of therapeutic effect is naive. It is reasonable, therefore, to take a multipronged approach with the paramount commonality that each model is related to human cancer through detailed molecular characterization.
The in vitro study of cancer cell lines is the only current method for characterizing therapeutic effect across hundreds of representative disease models derived from bona fide human tumors. The artificial nature of cell culture systems has many limitations, including a limit to the spectrum of human cancer that can be adequately represented. Nonetheless, cell-autonomous growth inhibitory effects can be robustly studied in many instances. Prior efforts at systematic profiling, including the NCI60, were limited by the small sample size and the lack of molecular characterization. Two efforts to rectify this deficit have now characterized both the molecular constituents and drug sensitivity of many hundreds of cell lines. The Cancer Cell Line Encyclopedia project (http:// www.broadinstitute.org/ccle) has completed the expression profiling, the copy number analysis, and the exon sequencing of 1600 genes across 949 cell lines available through commercial sources. The MGH-Sanger cell line project (Genomics of Drug Sensitivity in Cancer; http://www. cancerRxgene.org) has completed the expression and copy number analysis of 800 cancer cell lines, as well as exon sequencing of 65 genes commonly mutated in cancer. Full genomic exome sequencing will be completed by the end of 2011. These genomic parameters are being correlated with drug responses to a panel of 135 anticancer small molecules.
Renewed interest in studying human tumors without the requirement for in vitro growth has led to the development of primary human tumor explants for propagation in immunocompromised animals. This approach allows for the development of tumor models characterized by molecular alterations that appear difficult to maintain during in vitro growth. In addition, the function of key developmental pathways (e.g., the Hedgehog pathway) are much more likely to be preserved. Finally, the role of the murine stroma in supporting the growth of human cancers can in some instances reflect the human stromal response. For example, in pancreatic cancers, tumor production of Hedgehog ligands leads to stromal Hhpathway activation. In turn, inhibition of stromal Hh pathway activation by SMO inhibitors leads to an antitumor response (Yauch et al., 2008) .
Genetically engineered mouse (GEM) models have the intrinsic advantage of preserving stromal-to-epithelial interactions and a competent immune system. GEM models are increasingly reflective of the genetic alterations seen in some human cancers and likely harbor a high degree of genetic heterogeneity such that relevant resistance mechanisms can be rapidly identified (Buonamici et al., 2010) . These systems remain limited by the necessity of staging large numbers of mice for even rudimentary preclinical trials, and hence transplantable versions of GEM-derived tumors might provide a more tractable approach.
Finally, the rapid advances in nextgeneration sequencing throughput make it worth revisiting spontaneous or carcinogen-induced murine cancers, along with cancers arising in mice with targeted disruption of DNA repair pathways. Here, tumors can be collected in large numbers, and as sequencing costs drop, the full complement of genetic alterations will be understood. Such models could then be accepted or rejected as representatives of human disease based on a genetic comparison. This might allow the rapid development of a large array of genetically complex transplantable murine tumors. The growing evidence that preclinical models, when used in robust numbers and when accurately characterized, can be helpful in guiding clinical development should renew investment in building these models as a commonly available resource for wider-spread use.
Implications for Therapeutic Development in Nononcologic Diseases
The treatment of the majority of noninfectious medical illness remains largely based on phenotype. For example, diabetic therapy is largely confined to the lowering of blood glucose, the most readily measured ''phenotype'' of this complex disease. The progress toward understanding genetic mechanisms of disease has been notable in those medical illnesses caused by Mendelian inherited genetic alterations; however, progress in defining causally associated genetic variants has been slower. Limitations to progress in the genetic definition of medical disease have come in two forms: (1) the need to more precisely define distinct subdisease phenotypes so that genetically diverse diseases are not admixed and (2) an incomplete ability to analyze genetic variation, including rare variants across large sample sets. As is the case for cancer, we can see the near-term end of the second roadblock. And with sufficient attention to the first, the future discovery of new genetically defined pathways is likely. The discovery of complement pathway genetic variants as the largest attributable factor in the pathogenesis of macular degeneration is emblematic of the transformation that awaits (Edwards et al., 2005; Haines et al., 2005; Klein et al., 2005) .
Following the definition of diseasecausing genetic variants, the same challenges seen in cancer are likely to arise. First, the druggability gap will pose a substantial challenge. As an example, the identification of genetic alterations in hemoglobin has not led to a major advancement in medical therapy of sickle cell anemia and is reflective of the same difficulty faced in treating loss-of-function mutations in tumor suppressor genes. Though therapeutic resistance through a hypermutable genome is unlikely to be a common theme in nononcologic medical disease, adaptive resistance through pathway and endocrine remodeling likely suggests that combination therapy of medical illness will be essential.
Lastly, though cancer models are not ideal, the situation in the medical disease area is far worse. For most commonly used therapeutic models (collageninduced arthritis, chemical-induced fibrosis), we have little to no evidence that they mimic and/or reflect the human disease. Furthermore, in most cases, only one model system is used at all. Again, the likelihood that this testing paradigm will be predictive of human therapeutic success is low. A key challenge in these areas is to take emerging genetic data derived from patient-based studies and create models (likely starting with GEMs) based on the most relevant genetic alterations both alone and in combination.
The completion of the human genome project provided a roadmap to the eventual understanding of disease genomes. Genetic drivers of disease are now being elucidated and will allow us to transform the treatment of human illness. Though substantial, the hurdles to fully realizing this transformation can be overcome to drive the next stages of innovation and investment. 
